Article Archive for 17 June 2009
KMR GROUP, a firm analyzing biopharmaceutical R&D performance since the early 1990s, announces SiteView, its newest module in the Enrollment Metrix Application. Enrollment Metrix helps companies plan more effectively and reliably when setting recruitment …
KMR GROUP, a firm analyzing biopharmaceutical R&D performance since the early 1990s, announces SiteView, its newest module in the Enrollment Metrix Application. Enrollment Metrix helps companies plan more effectively and reliably when setting recruitment …
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal …
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal …
Abbott (NYSE: ABT) announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment …
Abbott (NYSE: ABT) announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment …
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), announced that it has obtained the rights to develop and market a novel agent for …
CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), announced that it has obtained the rights to develop and market a novel agent for …
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under …
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under …
Three Rivers Pharmaceuticals announced positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University, and colleagues at …
Three Rivers Pharmaceuticals announced positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University, and colleagues at …
